

Online supplement

Higher risk of future events, mortality, and greater healthcare use among patients with increasingly recurrent atherosclerotic cardiovascular disease events in Taiwan: a retrospective cohort study

Chia-Yun Hsu¹, Wen-Jone Chen², Hung-Ju Lin², Ho-Min Chen¹, Yea-Harn Yang³, Wei-Ju Chen³, Chieh-Min Chen⁴, Fei-Yuan Hsiao^{4,5,6*}

Contents

Table of Contents

Supplement 1 (Figure). Definition of subsequent events2

Supplement 2 (Figure). Selection flow of study population3

Supplement 3 (Figure). Recurrent event types by index events type5


Supplement 4 (Table). Probability of survival estimated by Kaplan–Meier method6

Supplement 5 (Table). Cumulative incidence rate of recurrent events considering competing risk estimated by Fine and Gray method7

Supplement 6 (Figure). Percentage of patients having cardiovascular-related healthcare use following each event.8

Supplement 7 (Figure). Percentage of patients prescribed with statin following each event9


Supplement 1 (Figure). Definition of subsequent events




Patients with an index event (population A), were further defined into subsets if they experienced a first recurrent event (population B) and a second recurrent event (population C). Post-event mortality was calculated and compared between each of these populations.

Supplement 2 (Figure). Selection flow of study population


(a) Patients with new-onset CHD



(b) Patients with new-onset CBVD




(c) Patients with new-onset PAD



CBVD, cerebrovascular disease; CHD, coronary heart disease PAD, peripheral artery disease

Supplement 3 (Figure). Recurrent event types by index events type



ASCVD: atherosclerotic cardiovascular disease; CBVD: cerebrovascular disease; CHD: coronary heart disease; PAD: peripheral artery disease

Supplement 4 (Table). Probability of survival estimated by Kaplan–Meier method

	Patients, n	Deaths, n	(%)	Probability of survival			
				6 mo	12 mo	18 mo	24 mo
Coronary heart disease							
Index event	97,321	21,773	(22.4)	0.889	0.859	0.836	0.815
First recurrent event	21,902	4,769	(21.8)	0.887	0.844	0.811	0.784
Second recurrent event	5,601	1,376	(24.6)	0.856	0.798	0.753	0.716
Cerebrovascular disease							
Index event	120,914	32,125	(26.6)	0.899	0.859	0.824	0.792
First recurrent event	25,337	6,540	(25.8)	0.881	0.830	0.787	0.750
Second recurrent event	6,644	1,528	(23.0)	0.884	0.833	0.795	0.753
Peripheral artery disease							
Index event	14,794	6,217	(42.0)	0.842	0.770	0.713	0.665
First recurrent event	5,951	2,412	(40.5)	0.821	0.737	0.672	0.622
Second recurrent event	2,463	924	(37.5)	0.817	0.725	0.663	0.607


mo, months.

Supplement 5 (Table). Cumulative incidence rate of recurrent events considering competing risk estimated by Fine and Gray method


	Patients, n	Events, n	(%)	Event rate			
				6 mo	12 mo	18 mo	24 mo
Coronary heart disease							
Index event	97,321	21,902	(22.5)	0.104	0.147	0.175	0.194
First recurrent event	21,902	5,601	(25.6)	0.134	0.196	0.237	0.263
Second recurrent event	5,601	1,731	(30.9)	0.196	0.273	0.327	0.360
Cerebrovascular disease							
Index event	120,914	25,337	(20.9)	0.110	0.140	0.162	0.180
First recurrent event	25,337	6,644	(26.2)	0.169	0.216	0.245	0.268
Second recurrent event	6,644	2,153	(32.4)	0.242	0.298	0.333	0.351
Peripheral artery disease							
Index event	14,794	5,951	(40.2)	0.241	0.301	0.338	0.367
First recurrent event	5,951	2,463	(41.4)	0.259	0.341	0.383	0.413
Second recurrent event	2,463	1,073	(43.6)	0.281	0.376	0.428	0.470

mo, months.

Supplement 6 (Figure). Percentage of patients having cardiovascular-related healthcare use following each event.



Supplement 7 (Figure). Percentage of patients prescribed with statin following each event



CBVD: cerebrovascular disease; CHD: coronary heart disease; PAD: peripheral artery disease.